The Psychedelics as Medicine Report (II)

 

 

Ver anterior:

The Psychedelics as Medicine Report (I)

 

 KEY TAKEAWAYS

1.-Medical psychedelics companies are valued at over US$10 billion.

2.-The market value of medical psychedelics is valued at US$190 million and expected to exceed US$2.4 billion by 2026. 

3.-The pandemic has great potential to rattle the mental health landscape, and psychedelic therapy offers another tool to support the alleviation of a growing global epidemic

A GROWING MARKET 

The market opportunity in the nascent and growing psychedelics’ space is being harnessed by a growing base of institutional investors seeking to establish and scale businesses in a landscape showing scientific and commercial promise. 

While capital invested in psychedelic companies is over US$2 billion, the current value of medical businesses surpasses US$10 billion, with atai Life Sciences’ initial public offering (IPO) earlier this year making it the most valuable publicly-traded business among the 47 publicly-traded businesses in the sector, currently valued at US$2.4 billion (as of September 2021). 

Biotech and pharmaceutical companies continue to dominate businesses within the sector, though there is a growing base - and appetite for - research clinics, therapy providers and software infrastructure. Canada’s capital markets remain a popular choice for psychedelic companies. 

There are over 100 ketamine clinics in operation in the USA with many more in the pipeline. Despite gaining regulatory approval in the UK, Johnson &Johnson’s Spravato (esketamine) did not receive approval by NICE (National Institute for Health and Care Excellence, which approves drugs for use by the National Health Service) twice, citing the cost-effectiveness estimates for esketamine to be much higher than the cost-effective use of National Health Service (NHS) resources, and would like to better understand the long-term use of esketamine in patients, and whether the improvement in symptoms and quality of life can be sustained follow - ing treatment. Spravato costs about £10,000 (US$14,000) per course of therapy. In the USA, it was suggested that the price of Spravato needs to be reduced by 40% in order to be cost-effective for the management of treatment-resistant depression (TRD).